Comparative Pharmacology
Head-to-head clinical analysis: CEFTIN versus CEFTRIAXONE IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CEFTIN versus CEFTRIAXONE IN PLASTIC CONTAINER.
CEFTIN vs CEFTRIAXONE IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Ceftin (cefuroxime axetil) is a second-generation cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), specifically transpeptidases, thereby disrupting peptidoglycan cross-linking. This leads to cell lysis and death primarily during active cell division.
Ceftriaxone inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), disrupting peptidoglycan cross-linking, leading to cell lysis mediated by autolytic enzymes. It has broad-spectrum activity against gram-positive and gram-negative bacteria.
250-500 mg orally twice daily for 10 days; for community-acquired pneumonia, 500 mg twice daily for 10 days. Intravenous: 750-1500 mg every 8 hours.
1-2 g intravenously or intramuscularly every 12-24 hours, maximum 4 g daily.
None Documented
None Documented
Terminal elimination half-life: 1-2 hours (normal renal function); prolonged to 15-20 hours in severe renal impairment (CrCl <10 mL/min).
5.8-8.7 hours in adults; prolonged in neonates (18-25 h), elderly, and renal impairment.
Renal: 80-90% unchanged via glomerular filtration and tubular secretion; biliary/fecal: <5%.
Renal (33-67% as unchanged drug), biliary/fecal (24-44% as active drug and metabolites).
Category C
Category C
Cephalosporin Antibiotic
Cephalosporin Antibiotic